Causes of Anaphylaxis in the Pediatric Population Ameiro, Beatriz, MD; Zambrano, Gabriela A., MD; Guzmán, Miguel, MD ...
Journal of allergy and clinical immunology,
02/2015, Letnik:
135, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Food allergy was identified in 93.1% of the cases: milk (47.8%), egg (25.4%), nuts (14.9%), fruits (7.5%) and fish (4.5%).
Angioedema Without Urticaria In The Emergency Department Torrado-Español, Ines, MD; Roa-Medellin, Dasha, MD; Rodriguez-Fernandez, Ana, MD ...
Journal of allergy and clinical immunology,
02/2017, Letnik:
139, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Rationale To determine the incidence and characteristics of angioedema without urticaria (AE) at the Emergency Department (ED) of a third-level Hospital in Madrid.
Adverse Reactions to Humanized Monoclonal Antibodies Roa-Medellin, Dasha, MD; Garcia-Gutierrez, Irene, MD; Lillo, Maria C., MD ...
Journal of allergy and clinical immunology,
02/2017, Letnik:
139, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Methods Observational study including all patients that were treated with MoAb from Jan-2010 to Dec-2015 in a third level hospital. Twenty-four (62.5% moderate-severe) underwent an Allergy study ...Seven had a positive skin test (infliximab 2, rituximab 2, belimumab 1, ustekinumab1, certolizumab 1).
Methods A retrospective analysis was performed in patients with severe spontaneous chronic urticaria (n=7), cholinergic urticaria with bad quality of life (n=1) and urticaria-vasculitis (n=1), ...treated with Omalizumab.
The Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection (HOME-CoV) rule is a checklist of eligibility criteria for home treatment of patients with COVID-19, defined using a ...Delphi method.
Is the HOME-CoV rule reliable for identifying a subgroup of COVID-19 patients with a low risk of adverse outcomes who can be treated at home safely?
We aimed to validate the HOME-CoV rule in a prospective, multicenter study before and after trial of patients with probable or confirmed COVID-19 who sought treatment at the ED of 34 hospitals. The main outcome was an adverse evolution, that is, invasive ventilation or death, occurring within the 7 days after patient admission. The performance of the rule was assessed by the false-negative rate. The impact of the rule implementation was assessed by the absolute differences in the rate of patients who required invasive ventilation or who died and in the rate of patients treated at home, between an observational and an interventional period after implementation of the HOME-CoV rule, with propensity score adjustment.
Among 3,000 prospectively enrolled patients, 1,239 (41.3%) demonstrated a negative HOME-CoV rule finding. The false-negative rate of the HOME-CoV rule was 4 in 1,239 (0.32%; 95% CI, 0.13%-0.84%), and its area under the receiver operating characteristic curve was 80.9 (95% CI, 76.5-85.2). On the adjusted populations, 25 of 1,274 patients (1.95%) experienced an adverse evolution during the observational period vs 12 of 1,274 patients (0.95%) during the interventional period: –1.00 (95% CI, –1.86 to –0.15). During the observational period, 858 patients (67.35%) were treated at home vs 871 patients (68.37%) during the interventional period: –1.02 (95% CI, –4.46 to 2.26).
A large proportion of patients treated in the ED with probable or confirmed COVID-19 have a negative HOME-CoV rule finding and can be treated safely at home with a very low risk of complications.
ClinicalTrials.gov; No.: NCT04338841; URL: www.clinicaltrials.gov;
When Is Epinephrine Used in Anaphylaxis? Alvarez-Perea, Alberto, MD; Tomás-Pérez, Margarita, MD; Ameiro, Beatriz, MD ...
Journal of allergy and clinical immunology,
02/2016, Letnik:
137, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Methods An observational study of all anaphylaxis at the general and pediatric Emergency Department (ED) was led in a third-level hospital in Madrid.
PDF
